The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?

Thrombosis and Haemostasis

Volumn 114, Issue 4, 2015, Pages 657-659

  Fauchier, Laurent ^a   Poli, Daniela ^b   Olshansky, Brian ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c North Iowa Mercy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; VITAMIN K GROUP;

ANTICOAGULATION; ASSESSMENT OF HUMANS; ATRIAL FIBRILLATION; CLINICAL DECISION MAKING; DRUG EFFICACY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SAME TT2R2 SCORE; SCORING SYSTEM; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; DECISION SUPPORT SYSTEM; DRUG EFFECTS; FEMALE; MALE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; VITAMIN K;

EID: 84943184812     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-06-0518     Document Type: Editorial

References (18)

1. Lip GYH, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORPAF Pilot registry). Eur Heart J 2014; 35: 3365-3376.
2. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
3. Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
4. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144: 1555-1563.
5. Ruiz-Ortiz M, Beromeu V, Ángel C, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114: 695-701.
6. Abumuaileq RR-Y, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with nonvalvular atrial fibrillation on vitamin-K antagonists. Europace 2015; 17: 711-717.
7. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient selfmanagement. J Thromb Thrombolysis 2000; 9: 283-292.
8. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
9. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15: 213-216.
10. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
11. Lip GYH, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT2R2 score to poorquality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
12. Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 9: 443-447.
13. Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014; 129: 1407-1414.
14. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-184S.
15. Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-2191.
16. Authors/Task Force Members, Camm AJ, Lip GYH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
17. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76.
18. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.